Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Keratosis, Actinic 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 16aldesleukin 14fludarabine 12fludarabine phosphate 11Interleukin-2 10montanide ISA 51 3Whole-Body Irradiation 2Radiation 2MART-1 Antigen 2Gefitinib 2sargramostim 1pembrolizumab 1peginterferon alfa-2a 1incomplete Freund's adjuvant 1flt3 ligand protein 1endonuclease V, phage T4 1Surgical Procedures, Operative 1Semaxinib 1Radiotherapy 1Peptides 1Lapatinib 1Interleukin-15 1Interleukin-12 1Early Intervention, Educational 1Deoxyribonuclease (Pyrimidine Dimer) 1Dasatinib 1Congresses as Topic 1Cholecalciferol 1B3(Fv)-PE38KDEL recombinant immunotoxin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Skin Neoplasms × endonuclease V, phage T4 × Clear all
NCT00089180 2015-12-04

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

National Cancer Institute (NCI)

Phase 2 Completed
100 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡